Cancer BiologybioRxivPreprint
BCMA/CD19 dual-targeting with FasTCAR: AZD0120 demonstrates potent preclinical efficacy in multiple myeloma
Huan Shi, Wenjie Yin, Hua Zhang…·Lianjun Shen
This paper evaluates AZD0120, a dual-targeting BCMA/CD19 CAR-T therapy, showing improved preclinical efficacy and tumor control in multiple myeloma models.
DOI 10.64898/2026.06.05.730120